Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
NCT00004092
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different regimens of combination chemotherapy and comparing them to see how well they work in treating patients with high-risk primary stage II or stage III breast cancer.
Gender:
ALL
Ages:
60 years and below
Trial Updated:
07/07/2015
Locations: Banner Good Samaritan Medical Center, Phoenix, Arizona +1 locations
Conditions: Breast Cancer
Register for Updates
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
NCT02446431
Recruiting
Most pediatric patients with solid tumors respond to initial high-dose, intensive therapy and complete treatment in remission. High-risk patients however, frequently have recurrent disease which is then treated with ad hoc regimens or early phase therapies with little benefit to the patient. Metronomic therapy (MC), defined as lower dose continuous drug exposure, has been successfully tested in pediatric leukemias with excellent results in terms of improved outcome, toxicity profiles, and cost.... Read More
Gender:
ALL
Ages:
Between 12 months and 31 years
Trial Updated:
05/13/2015
Locations: Miller Children's and Women's Hospital Long Beach, Long Beach, California +1 locations
Conditions: Solid Tumor
Register for Updates
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00072566
Completed
This phase II trial is to see if combining bevacizumab with low-dose cyclophosphamide works in treating patients with ovarian epithelial or primary peritoneal cancer that has come back or spread to other parts of the body. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy, such as cyclo... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
05/08/2015
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Ovarian Cancer
Register for Updates
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer
NCT00022230
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining chemotherapy with biological therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving chemotherapy together with biological therapy and to see how well they work in treating patients with stage II or stage III breas... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/04/2015
Locations: Roger Williams Medical Center, Providence, Rhode Island
Conditions: Breast Cancer
Register for Updates
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML
NCT00669890
Terminated
The addition of gemtuzumab ozogamicin (GO) in combination with Busulfan/Cyclophosphamide followed by AlloSCT in patients with high risk CD33+ AML/JMML/MDS will be safe and well tolerated. This study will attempt to determine the maximum tolerated dose of the immune therapy (gemtuzumab) when given in combination with the myeloablative (high dose) drugs used in this study for allogeneic stem cell transplant. (Part A)
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/20/2015
Locations: Morgan Stanley Children's Hospital of NYP, New York City, New York
Conditions: Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Register for Updates
Effects of Exercise in Combination With Epoetin Alfa
NCT00577096
Completed
The purpose of the study was to determine the effect of Epoetin alfa therapy (short term versus long term) with and without a home-based individualized exercise program that incorporated aerobic and strength resistance training for patients being treated with high-dose chemotherapy and autologous peripheral bloodstem cell transplantation (PBSC T) for multiple myeloma. The endpoints for the study included the number of attempts at and total number of days of stem cell collection, number of RBC an... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/02/2015
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
NCT00958256
Completed
The goal of this clinical research study is to learn if bortezomib when given in combination with cyclophosphamide and rituximab can help to control mantle cell lymphoma. The safety of this drug combination will also continue to be studied.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/31/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Mantle Cell Lymphoma, Lymphoma
Register for Updates
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
NCT00146588
Completed
The purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/23/2015
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Register for Updates
SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia
NCT00002665
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with or without bone marrow transplantation in treating patients who have acute lymphocytic leukemia.
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
03/05/2015
Locations: MBCCOP - University of South Alabama, Mobile, Alabama +82 locations
Conditions: Leukemia, Neutropenia, Thrombocytopenia
Register for Updates
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
NCT00723658
Withdrawn
RATIONALE: Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. Giving combination chemotherapy together with bortezomib, thalidomide, and rituximab before an autologous peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. More chemotherapy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut +28 locations
Conditions: Lymphoma
Register for Updates
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00109837
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), and giving the drugs in different combinations may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/05/2015
Locations: Providence Saint Joseph Medical Center - Burbank, Burbank, California +77 locations
Conditions: Leukemia
Register for Updates
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
NCT00005834
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known if combination chemotherapy is more effective with or without thalidomide for multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without thalidomide in treating patients who have refractory multiple myeloma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +92 locations
Conditions: Multiple Myeloma
Register for Updates